Strong Week for Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Doesn't Alleviate Pain of Five-year Loss
Strong Week for Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Doesn't Alleviate Pain of Five-year Loss
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders for doubting their decision to hold, with the stock down 19% over a half decade. The falls have accelerated recently, with the share price down 17% in the last three months.
股票挑选的主要目标是寻找跑赢市场的股票。但是,每个投资者几乎肯定会拥有表现超预期和表现不如预期的股票。因此,长期持有Supernus Pharmaceuticals,Inc.(NASDAQ:SUPN)股票下跌19%有半个十年的股东们可能对他们的决定开始产生怀疑。股价在最近几个月内大幅下跌,已下跌17%。
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
虽然过去一周股东的投资回报率有所缓解,但在过去五年中仍处于亏损状态,因此让我们看看这家公司的基本业务是否是导致下跌的原因。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
市场有时无疑是高效的,但价格并不总是反映基础业务表现。 一种检查市场情绪如何随时间改变的方法是查看公司的股价与每股收益(EPS)之间的互动。
In the last half decade Supernus Pharmaceuticals saw its share price fall as its EPS declined below zero. This was, in part, due to extraordinary items impacting earnings. At present it's hard to make valid comparisons between EPS and the share price. However, we can say we'd expect to see a falling share price in this scenario.
在过去的半个十年里,随着每股收益下降至零以下,Supernus Pharmaceuticals的股价下跌。这在一定程度上是由于影响收益的特殊项目。目前,很难对比每股收益和股价。然而,我们可以说,在这种情况下,我们预计会看到股价下跌。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-c641b7a0207e2e98738470b07930f5c2-0-e55aecf83d6e1080663f5ec8f855ed76.png/big)
Dive deeper into Supernus Pharmaceuticals' key metrics by checking this interactive graph of Supernus Pharmaceuticals's earnings, revenue and cash flow.
通过查看Supernus Pharmaceuticals的收益、营业收入和现金流量的交互式图形,深入了解Supernus Pharmaceuticals的关键指标。
A Different Perspective
不同的观点
Supernus Pharmaceuticals shareholders are down 11% for the year, but the market itself is up 26%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Before spending more time on Supernus Pharmaceuticals it might be wise to click here to see if insiders have been buying or selling shares.
Supernus Pharmaceuticals的股东们今年已经下跌了11%,但市场本身则上涨了26%。但是请记住,即使是最好的股票有时也会在12个月的时间内表现不如市场。不幸的是,去年的表现推动了一波衰减,股东们面临的亏损累计每年达3%。我们意识到巴伦·罗斯柴尔德曾说过投资者应该“在街头流血的时候买进”,但我们提醒投资者首先要确保他们正在购买高质量的业务。在花更多时间研究Supernus Pharmaceuticals之前,可能最好先单击此处查看内部人是否一直在买卖股票。
For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找获胜投资的人来说,最近有内部购买的低估公司免费列表可能是一个很好的选择。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com